Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects

International Journal of STD and AIDS

Volumn 22, Issue 4, 2011, Pages 228-230

  Smith, D E ^a   Chan, D J ^a   Maruszak, H ^a   Jeganathan, S ^a  

^a Albion Street Centre ^*  (Australia)

Author keywords

Antiretroviral therapy; HIV 1; Nevirapine; Tenofovir

Indexed keywords

EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; TENOFOVIR;

ADULT; ARTICLE; BRAIN DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL;

ADENINE; ADULT; ANTI-HIV AGENTS; AUSTRALIA; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; LOST TO FOLLOW-UP; MALE; MEDICAL AUDIT; MIDDLE AGED; NEVIRAPINE; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 79955621882     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2010.010258     Document Type: Article

References (18)

1. Post J, Kelly M, Drummond F, et al. Australian commentary on guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. November 2008. See http://www.ashm.org.au/projects/arvguidelines/images/ASHMPublications/pdf/201006_arv_guidelines_with_aus_commentary.pdf (last checked 15 March 2010)
2. Bartlett JG, Lane CH, Pau AK, et al. Panel on antiretroviral guidelines for adult and adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. 10 October 2006:1-113. See http://aidsinfo.nih.gov/Guidelines/Default.aspx (last checked 12 March 2010)
3. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-1263
4. Lapadula G, Costarelli S, Quiros-Roldan E, et al. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis 2008;46:1127-1129
5. Rey D, Hoen B, Chavanet P, et al. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother 2009;63:380-388
6. Martinez E, Arnaiz JA, Podzamczer D, et al. Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients. AIDS 2007;21:367-369
7. Podzamczer D, Olmo M, Sanz J, et al. Safety of switching nevirapine twice daily to nevirapine once daily in virologically suppressed patients. J Acquir Immune Defic Syndr 2009;50:390-396
8. Colafigli M, Di Giambenedetto S, Bracciale L, et al. Long-term follow-up of nevirapine-treated patients in a single-centre cohort. HIV Med 2009;10:461-469
9. Gil P, de Gorgolas M, Estrada V, et al. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load. Clin Infect Dis 2004;39:1024-1029
10. Klauke S, Cairns V, Goldbach J. Interim analysis (24 months) of a non-interventioal cohort study of patients treated with nevirapine in combination with tenofovir plus emtricitabine. 12th European AIDS Conference, 2009; Cologne, Germany
11. Labarga P, Medrano J, Seclen E, et al. Safety and efficacy of tenofovir/ emtricitabine plus nevirapine in HIV-infected patients. AIDS 2010;24:777-779
12. Schewe C, Noah C, Adam A, et al. Switch to antiretroviral regimens containing tenofovir (TDF) and nevirapine (NVP). A retrospective analysis of efficacy and tolerability. 10th European AIDS Conference; 17-20 November 2005; Dublin, Ireland. Poster PE 7.5/6
13. Weberschock T, Gholam P, Hueter E, Flux K, Hartmann M. Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: A 72-week prospective multicenter study (TENOR-Trial). Eur J Med Res 2009;14:516-519
14. Soriano V, Koppe S, Migrone H, et al. Prospective randomised comparison of Nevirapine and Atazanavir/ritonavir both combined with Tenofovir DF/ Emtricitabine in treatment-nai{dotless}̈ve HIV-1 infected patients: ARTEN Study week 48 results. 5th IAS Congress, 2009; Cape Town, South Africa
15. Maggiolo F, Arici C, Airoldi M, et al. Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort. J Antimicrob Chemother 2007;59:569-572
16. Keiser P, Nassar N, White C, Koen G, Moreno S. Comparison of nevirapine-and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials 2002;3:296-303
17. Phillips AN, Pradier C, Lazzarin A, et al. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001;15:2385-2395
18. Bonjoch A, Paredes R, Domingo P, et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2006;22:321-329